Acepodia Inc.’s antibody cell conjugation platform could change the way CAR T-cell therapies are manufactured, clearing the way for an off-the-shelf model to treat numerous cancers that is safer and ...

Through Pfizer Ignite, Acepodia will gain access to Pfizer's resources, scale and expertise as the company broadens the application of its platform beyond oncology into autoimmune diseases Pfizer ...

First dosing dohort was completed with complete response and disease stabilization identified at three months at the lowest dose level in the Phase 1 study One out of five patients demonstrated ...